Male Infertility Market is expected to reach US$ 6,213.96 Mn in 2027

DNA Fragmentation Technique Segment to Register Highest CAGR in Male Infertility Market during 2020–2027

According to our new market research study on “Male Infertility Market – Global Analysis and Forecast – by Test, Treatment Type, Distribution Channel, and End-User,” the market is expected to reach US$ 6,213.96 million by 2027 from US$ 3,883.82 million in 2019; it is estimated to grow at a CAGR of 6.2% from 2020 to 2027. The report highlights the trends prevailing in the global male infertility market, and the drivers and deterrents pertaining to its growth. The growth of the male infertility market is attributed to the increase in male infertility worldwide and technological advancements. However, high cost of procedures hampers the growth of the market.

The male infertility market, by test, is segmented into DNA fragmentation technique, oxidative stress analysis, computer assisted semen analysis, microscopic examination, sperm agglutination, sperm penetration assay, and others. The DNA fragmentation technique segment held the largest share of the market in 2019, whereas the computer assisted semen analysis segment is anticipated to register the highest CAGR of 7.2% in the market during the forecast period. The growing adoption of advanced and improved assisted reproductive technologies, and rise in infertility ratio among males are among the factors augmenting the growth of the male infertility market for the DNA fragmentation technique. Further the rise in the market for computer-assisted semen analysis can be attributed to the growing emphasis of various manufacturers on offering innovative products. For instance, in June 2017, MICROPTIC collaborated with Embryotools for to develop a sperm analysis system in their lab and conduct training for the operations of the same.

MERCK KGaA, Sanofi, Bayer AG, Endo Pharmaceuticals Inc., SCSA Diagnostics, Inc., Andrology Solutions, Halotech DNA, INTAS PHARMACEUTICALS LTD., Cadila Pharmaceuticals Ltd.; and Vitrolife  are among the prominent players operating in the male infertility market. The key companies are focused on organic and inorganic strategies to sustain their position in the market. For instance, in January 2020, Merck KGaA received an approval from the European Commission (EC) for its new GONAL-f (follitropin alfa) 150 IU pen, with A goal to strengthen its fertility-related product portfolio for European countries.

Male Infertility Market, by Region, 2019 (%)

The Report Segments the Global Male Infertility Market as Follows:

By Test

• DNA Fragmentation Technique
• Oxidative Stress Analysis
• Microscopic Examination
• Sperm Agglutination
• Computer Assisted Semen Analysis
• Sperm Penetration Assay
• Others

By Treatment Type

• Assisted Reproductive Technology and Varicocele Surgery
• Medication

By Distribution Channel

• Hospitals Pharmacies
• Pharmacies and Drug Stores
• Online Pharmacies

By End User

• Hospitals and Clinics
• Fertility Centers
• Research Institutes
• Other End Users

By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific (APAC)
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Rest of MEA
• South and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of SCAM

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com